BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices used in interventional medical specialties. The reporting period includes the full results of the Cardiac Rhythm Management (CRM) and Cardiac Surgery businesses acquired from Guidant Corporation in April 2006.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales decreased 2% in Q2 2007 compared to Q2 2006 ($2.071B vs $2.110B) but increased 11% for the six-month period ($4.157B vs $3.730B). The six-month increase was driven by the inclusion of a full period of CRM and Cardiac Surgery sales.
• Profitability: The company returned to profitability with Net Income of $115 million in Q2 2007, a significant turnaround from a Net Loss of $4.262 billion in Q2 2006. The prior year loss was heavily impacted by $4.424 billion in purchase accounting adjustments related to the Guidant acquisition.
• Product Mix: U.S. sales of drug-eluting coronary stents declined significantly due to a contraction in market size and concerns regarding late stent thrombosis. Conversely, CRM sales grew, though U.S. CRM sales were impacted by a product advisory issued in April 2007.
• Expenses: Operating expenses increased due to the integration of Guidant operations, though amortization and royalty expenses decreased compared to the prior year due to the absence of specific Guidant-related write-offs and lower stent sales volumes.

Outlook, Risks, and Management Commentary

• Market Outlook: Management expects continued pressure on U.S. drug-eluting stent sales until the market stabilizes. International stent sales face competitive pressure from new product launches. The CRM market is expected to see slow but sustained growth as the company works to regain physician confidence following product advisories.
• Debt and Liquidity: The company carries significant debt ($8.9 billion) from the Guidant acquisition. Credit ratings were downgraded to non-investment grade (BB+ by S&P/Fitch, Ba1 by Moody's) in mid-2007. The company remains in compliance with debt covenants (Debt/EBITDA ratio of 4.0:1).
• Strategic Initiatives: Management is pursuing cost reduction measures, including headcount reductions and the potential sale of non-strategic assets (e.g., fluid management business) to improve cash flow for debt repayment.
• Legal and Regulatory: Significant litigation risks remain, including patent disputes with Johnson & Johnson and Medtronic, and product liability claims related to Guidant's CRM devices. A settlement of $195 million was reached in July 2007 for certain CRM product liability claims. The company is also addressing FDA warning letters regarding quality systems.
• Unusual Items: Q2 2007 results included a $15 million credit to purchased R&D from terminating an agreement with Aspect Medical Systems and investment portfolio writedowns of approximately $20 million.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the company's ability to maintain the required Debt-to-EBITDA ratio (4.5:1 through end of 2007) given the high debt load and potential revenue volatility.
• CRM Recovery: Monitor the impact of the April 2007 product advisory on CRM sales and the timeline for regaining market share and physician trust.
• Stent Market Dynamics: Assess the duration of the U.S. drug-eluting stent market contraction and the competitive impact of Abbott's XIENCE/PROMUS launch.
• Legal Exposure: Review the status of the $706 million legal accrual and potential additional liabilities from the Guidant acquisition, particularly regarding the ANCURE system and CRM devices.
• Cost Reduction Execution: Track the progress of restructuring plans and asset divestitures intended to align expenses with revenue levels.